Clinical Trial Update: Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated Magnevist-enhanced MRA versus non-contrast MRA for detecting structural abnormalities of the aortic arch and cerebral branches; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Aneurysm
• Cardiovascular Disease
• Cerebral Aneurysm

Drugs mentioned

• Magnevist (gadopentetate dimeglumine)

Snippet

Sponsor: Bayer | Conditions: Cardiovascular Abnormalities | Phase 3 | Status: COMPLETED